Michael Klichinsky's most recent trade in Carisma Therapeutics Inc was a trade of 221,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Jan. 28, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Carisma Therapeutics Inc | Michael Klichinsky | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 221,000 | 221,000 | - | - | Stock Option (Right to Buy) | |
Carisma Therapeutics Inc | Michael Klichinsky | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
Carisma Therapeutics Inc | Klichinsky Michael | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2024 | 170,500 | 170,500 | - | - | Stock Option (Right to Buy) | |
Carisma Therapeutics Inc | Michael Klichinsky | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 238,000 | 238,000 | - | - | Stock Option (Right to Buy) |